Aap Implantate AG Enhances Profitability in H1 2026 Amid Market Challenges

aap Implantate AG reports improved profitability for the first half of 2026, despite regional setbacks. The company's EBITDA loss reduction, coupled with regulatory milestones, positions it positively for the year's second half. Significant developments include FDA approval for the LOQTEQ® VA Proximal Humerus System and the launch of a fully MDR-certified product.

Regional performances varied. Sales in EMEA, making up 50% of total revenues, faced disruptions due to Middle East conflicts. In contrast, Spain, Portugal, and Germany showed growth. Latin America saw mixed results, with Mexico and Chile recording double-digit growth despite issues in Brazil and Venezuela. In the APAC region, Taiwan's sales advanced, while prior investments affected overall revenues. The US subsidiary maintained momentum, achieving its first-ever local positive result.

With strategic measures and investments, aap expects to leverage its strong order book and new products for continued growth, despite lingering regulatory challenges in antibacterial silver implant technology.